Quantification of γδ T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment

BACKGROUND: Natalizumab (NTZ) is a drug that has been widely used in the treatment of multiple sclerosis (MS). NTZ is very effective in suppressing inflammation, but if treatment is suspended many patients will experience relapses. OBJECTIVE: To investigate if quantification of γδ T cells and HLA-DR...

Descripción completa

Detalles Bibliográficos
Autores principales: Paužuolis, Mindaugas, Eich, Torsten, Burman, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460885/
https://www.ncbi.nlm.nih.gov/pubmed/28586378
http://dx.doi.org/10.1371/journal.pone.0179095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460885/
https://www.ncbi.nlm.nih.gov/pubmed/28586378
http://dx.doi.org/10.1371/journal.pone.0179095

Ejemplares similares